IMSA101 and Radiotherapy with Immunotherapy for Metastatic Kidney Cancer
Tests IMSA101 with radiotherapy and nivolumab in adults with spreading kidney cancer.
Plain-language title generated from the registry record
Registry title: Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
Key facts
- Where
- Dallas, United StatesSee the site
- Phase
- Phase 2
Where in United States
- University of Texas Southwestern Medical CenterDallas, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Texas Southwestern Medical Center
- Trial code
- NCT06601296
- Record updated
- 29 October 2026
- Original description
To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).Read full original descriptionShow less
STING Agonist and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer.
To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
Inclusion: Patients must have metastatic ccRCC; Patients must have oligoprogressive disease (up to 5 progressing lesions) on any ongoing or prior check-point inhibitor regimen that are all amenable to radiation including one lesion suitable for IMSA101 injection; Karnofsky Performance Status (KPS) of at least 50%; Life expectancy of at least 6 months; Age ≥ 18 years; Patients must have adequate organ and marrow function within 14 days prior to study entry; All IMDC risk categories are allowed.
Exclusion: Prior high-grade toxicity from check-point inhibitors deemed to place he patient at high risk for toxicity recurrence with re-challenge with check-point inhibitors; Prior STING agonist use; Any condition requiring systemic treatment with corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; Uncontrolled adrenal insufficiency.